FDA approvals

FDA Alerts

FDA Approves Relugolix for Advanced Prostate Cancer

12/18/2020

Journal of Clinical Pathways

FDA Alerts

FDA Approves Margetuximab for Metastatic Breast Cancer

12/17/2020

Journal of Clinical Pathways

News

FDA Approves Pralsetinib for Thyroid Cancers Harboring RET Alterations

12/01/2020

Journal of Clinical Pathways

News

FDA Approves Radioactive Diagnostic Agent for Prostate Cancer

12/01/2020

Journal of Clinical Pathways

FDA Alerts

FDA Approves Naxitamab for Neuroblastoma in Bone or Bone Marrow

11/28/2020

Journal of Clinical Pathways

News

ACCC Releases Report on Current State of Immuno-Oncology

07/01/2020

The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute released an assessment of the current state of immuno-oncology that highlights for cancer care professionals the current research,...

The...

07/01/2020

Journal of Clinical Pathways

Interview

Novel Ibrutinib Combination for Primary Treatment of CLL

06/22/2020

On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...

On...

06/22/2020

Journal of Clinical Pathways

Research in Review

Trastuzumab Biosimilar Approval Could Improve Access to Treatment For Breast Cancer

12/05/2016

JCP Editors

The potential FDA approval of a new biosimilar to trastuzumab may help increase access to the treatment, which is recommended as first-line therapy for patients with ERBB2 (HER2)-positive breast...

The...

12/05/2016

Journal of Clinical Pathways

Major Changes to NCCN Guidelines for Multiple Myeloma Announced

04/05/2016

JCP Editors

The National Comprehensive Cancer Network (NCCN) has announced three major changes to its guidelines for the treatment of multiple myeloma (MM) that broaden the population of patients eligible to start therapy,...

The...

04/05/2016

Journal of Clinical Pathways

Understanding New Treatments for Chronic Lymphocytic Leukemia

04/04/2016

JCP Editors

Recent Food and Drug Administration (FDA) approvals have changed the landscape of treatment for chronic lymphocytic leukemia (CLL). In a session at the 2016 National Comprehensive Cancer Network (NCCN) Annual...

Recent...

04/04/2016

Journal of Clinical Pathways